secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001544784-24-000068
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path Q1 net loss $3.2M ($4.88/sh); raises $3.5M post-quarter
----------------------------------------------------------------

- Net loss $3.2M ($4.88 EPS) vs $5.3M ($13.25 EPS) in Q1 2023; R&D expense down to $2.3M from $4.0M.
- Cash at Mar 31 only $0.2M; raised $3.5M in April via $1.2M direct offering and $2.3M ATM sales.
- Completed second dose cohort (40 mg/m2) of Phase 1/1b BP1002 trial for relapsed AML; pause for FDA review.
- Patent portfolio expanded to 5 U.S. and 54 foreign patents covering 21 countries; new applications filed.
- First dose cohort of Phase 1 BP1002 trial for relapsed lymphoma/CLL completed in January.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000154478424000068/0001544784-24-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000154478424000068/bpth-20240515x8k.htm
  HTML page:      https://secwatch.observer/filing/0001544784-24-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer